Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.7481
Nov 17 • 3:59 PM ET Dollar change+0.0414 Percentage change(5.86%)
Aftermarket Close
0.7707
Aftermarket • 7:37 PM ET Dollar change+0.0226 Percentage change(3.02%)
Nov 16, 4:36 PMiBio reports 28-week preclinical IBIO-610 data showing 2.3% vehicle-adjusted body-weight reduction
Index
-
Market Cap
52.71M
Enterprise Value
-21.87M
Income
-34.88M
Sales
1.07M
Book/sh
1.22
Cash/sh
1.09
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
23
IPO
Aug 19, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
49.26
P/B
0.61
P/C
0.69
P/FCF
-
EV/EBITDA
-
EV/Sales
-20.44
Quick Ratio
9.48
Current Ratio
9.48
Debt/Eq
0.03
LT Debt/Eq
0.02
Option/Short
No / Yes
EPS (ttm)
-0.40
EPS next Y
-0.52
EPS next Q
-0.08
EPS this Y
-3.47%
EPS next Y
-58.05%
EPS next 5Y
-26.38%
EPS past 3/5Y
85.59% 64.94%
Sales past 3/5Y
- -46.91%
EPS Y/Y TTM
71.61%
Sales Y/Y TTM
115.00%
EPS Q/Q
53.89%
Sales Q/Q
975.00%
Insider Own
8.54%
Insider Trans
0.00%
Inst Own
60.08%
Inst Trans
12.90%
ROA
-45.65%
ROE
-51.82%
ROIC
-43.55%
Gross Margin
7.63%
Oper. Margin
-3025.58%
Profit Margin
-3244.19%
SMA20
-3.11%
SMA50
-21.71%
SMA200
-53.41%
Trades
Shs Outstand
70.46M
Shs Float
64.44M
52W High
3.82 -80.42%
52W Low
0.68 10.81%
Volatility
11.10% 9.52%
ATR (14)
0.07
RSI (14)
42.01
Beta
1.48
Rel Volume
0.77
Avg Volume
697.57K
Volume
533,845
Perf Week
-4.09%
Perf Month
-1.58%
Perf Quarter
-49.79%
Perf Half Y
-50.13%
Perf YTD
-61.24%
Perf Year
-31.99%
Perf 3Y
-85.62%
Perf 5Y
-99.79%
Perf 10Y
-99.97%
Prev Close
0.71
Price
0.75
Change %
5.86%
Consensus
Strong Buy
Avg. Price Target
$5.69
Implied Upside
+660.6%
Analysts9incl. previous ratings
Rating Distribution9 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 17, 2026Initiated
HH.C. Wainwright
Buy$7+835.7%
Jun 08, 2026Initiated
RJF logoRRaymond James
Outperform$5+568.4%
Jun 05, 2026Initiated
RILY logoRB. Riley Securities
Buy$6+702.0%
Oct 21, 2025Initiated
OPY logoOOppenheimer
Outperform$5+568.4%
Oct 17, 2025Initiated
LLeerink Partners
Outperform$2+167.3%
May 28, 2024Initiated
CChardan Capital Markets
Buy$5+568.4%
Nov 29, 2021Initiated
JJMP Securities
Mkt Outperform$1.50+100.5%
Jan 22, 2021Initiated
CCantor Fitzgerald
Overweight$3+301.0%
Jun 26, 2020Initiated
AAlliance Global Partners
Buy$2.55+240.9%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Banjak MarcChief Legal OfficerMar 26 '26Buy1.6513,93423,05525,000Mar 27 04:05 PM
Duran FelipeChief Financial OfficerMar 19 '26Buy2.0224,83550,13235,974Mar 23 07:31 AM
Brenner MartinSee RemarksMar 19 '26Buy2.0212,33624,91930,652Mar 23 07:30 AM
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.
Ph.D.Dr. Martin B. Brenner D.V.M.
CFO & Principal Accounting OfficerMr. Felipe Duran
Chief Legal Officer & Corporate SecretaryMr. Marc Banjak J.D.
Chief Medical OfficerDr. Molly Carr M.D.